Drug reference
relacorilant
Selective glucocorticoid receptor antagonist · Glucocorticoid receptor antagonist
Selective glucocorticoid receptor antagonistGlucocorticoid receptor antagonist
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
An orally available, high-affinity, selective antagonist for the glucocorticoid receptor. Unlike mifepristone, it does not have appreciable affinity at the progesterone receptor.
Indications
endogenous cushing syndrome (under clinical trials)adrenocortical carcinoma (under clinical trials)
Related guidelines
Empirical antimicrobial use in common syndromes
ICMR · Infectious Diseases · 2019
Acute coronary syndrome in chronic kidney disease
CSI · Cardiology · 2020
Sjögren's syndrome
EULAR · Rheumatology · 2025
Primary PCI for acute coronary syndrome
ESC · Cardiology · 2026
Irritable bowel syndrome
ISG · Gastroenterology · 2023
Ask House about relacorilant
Continue into a citation-backed clinical answer with the drug context already attached.
Textbook-sourced·Sources: Goodman & Gilman 14e·Updated: 2026-05-10